Literature DB >> 2642098

Connective tissue metabolism in children with chronic renal failure.

L Klujber1, S Turi, I Haszon, Z Baranyai, E Sulyok.   

Abstract

To assess the characteristics of connective tissue metabolism in chronic renal failure (CRF), urinary excretion of glycosaminoglycan (GAG) fractions and hydroxyproline (HYP) was determined in ten patients with CRF and in ten age-matched healthy children. CRF was found to be associated with elevated free HYP (19.9 +/- 6.1 vs 9.8 +/- 3.6 mumol/day, P less than 0.05) and depressed peptide HYP excretion (33.1 +/- 13.5 vs 225.2 +/- 17.7 mumol/day, P less than 0.01), a low rate of total GAG excretion (7.0 +/- 2.4 vs 16.1 +/- 1.9 mumol uronic acid/day, P less than 0.05) with low chondroitin 4 -sulphate + chondroitin 6 -sulphate (Ch-Ss) (14.0 +/- 9.9 vs 65.0 +/- 22.1%) and a high proportion of non-sulphated or under-sulphated fractions, i.e. hyaluronic acid + chondroitin + heparan sulphate (HA + Ch + HS) (75.3 +/- 11.4 vs 31.5 +/- 5.7%). Urinary 3-methyl-histidine (3-met-HIS) excretion and plasma essential free amino acids did not differ in the two groups. In response to haemodialysis no consistent change occurred in urinary excretion of 3-met-HIS, peptide-bound HYP, total GAG or percentage distribution of individual GAG fractions. After haemodialysis all plasma amino acids decreased significantly, and there was a significant increase in urinary excretion of free HYP (P less than 0.05). We conclude that the alterations in urinary excretion of total and individual GAGs observed in CRF may reflect disturbed connective tissue metabolism which does not appear to be accounted for by protein malnutrition or enhanced protein breakdown and remains uninfluenced by haemodialysis therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642098     DOI: 10.1007/bf00852905

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

Review 1.  Protein and amino acid metabolism in uremic patients undergoing maintenance hemodialysis.

Authors:  J D Kopple; M E Swendseid
Journal:  Kidney Int Suppl       Date:  1975-01       Impact factor: 10.545

2.  Modifications of a specific assay for hydroxyproline in urine.

Authors:  K I Kivirikko; O Laitinen; D J Prockop
Journal:  Anal Biochem       Date:  1967-05       Impact factor: 3.365

3.  Alport familial nephritis. Absence of 28 kilodalton non-collagenous monomers of type IV collagen in glomerular basement membrane.

Authors:  M M Kleppel; C E Kashtan; R J Butkowski; A J Fish; A F Michael
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

Review 4.  Collagen metabolism, uremia and bone.

Authors:  L V Avioli
Journal:  Kidney Int       Date:  1973-08       Impact factor: 10.612

5.  Urinary glycosaminoglycan excretion in normally grown and growth retarded neonates. I. Total glycosaminoglycan excretion.

Authors:  L Klujber; E Sulyok
Journal:  Acta Paediatr Acad Sci Hung       Date:  1972

6.  3-Methylhistidine as a measure of skeletal muscle protein breakdown in human subjects: the case for its continued use.

Authors:  F J Ballard; F M Tomas
Journal:  Clin Sci (Lond)       Date:  1983-09       Impact factor: 6.124

7.  A rapid colorimetric method for 3-methylhistidine in urine.

Authors:  E Radha; S P Bessman
Journal:  Anal Biochem       Date:  1982-03-15       Impact factor: 3.365

8.  Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia.

Authors:  R Hällgren; A Engström-Laurent; U Nisbeth
Journal:  Nephron       Date:  1987       Impact factor: 2.847

9.  The urinary excretion of total hydroxylysine and its glycosides in normal persons, and in patients suffering from Alport's syndrome--contribution of the peptide-bound fraction.

Authors:  C H Schröder; L A Monnens; H M van Lith-Zanders; J M Trijbels; J H Veerkamp
Journal:  Nephron       Date:  1987       Impact factor: 2.847

10.  Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin.

Authors:  H Shimomura; R G Spiro
Journal:  Diabetes       Date:  1987-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.